Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does INOTUZUMAB OZOGAMICIN Cause Hyperphosphataemia? 10 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 10 reports of Hyperphosphataemia have been filed in association with INOTUZUMAB OZOGAMICIN (Besponsa). This represents 0.4% of all adverse event reports for INOTUZUMAB OZOGAMICIN.

10
Reports of Hyperphosphataemia with INOTUZUMAB OZOGAMICIN
0.4%
of all INOTUZUMAB OZOGAMICIN reports
0
Deaths
1
Hospitalizations

How Dangerous Is Hyperphosphataemia From INOTUZUMAB OZOGAMICIN?

Of the 10 reports, 1 (10.0%) required hospitalization, and 3 (30.0%) were considered life-threatening.

Is Hyperphosphataemia Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for INOTUZUMAB OZOGAMICIN. However, 10 reports have been filed with the FAERS database.

What Other Side Effects Does INOTUZUMAB OZOGAMICIN Cause?

Death (253) Febrile neutropenia (230) Venoocclusive liver disease (229) Neoplasm progression (158) Pyrexia (151) Off label use (146) Sepsis (119) Venoocclusive disease (109) Thrombocytopenia (108) Platelet count decreased (107)

What Other Drugs Cause Hyperphosphataemia?

ALLOPURINOL (139) LANSOPRAZOLE (138) ACETAMINOPHEN (132) SEVELAMER (129) ONDANSETRON (127) CALCITRIOL (125) IPRATROPIUM (123) ALBUTEROL (122) METRONIDAZOLE (120) HYDROMORPHONE (118)

Which INOTUZUMAB OZOGAMICIN Alternatives Have Lower Hyperphosphataemia Risk?

INOTUZUMAB OZOGAMICIN vs INSULIN INOTUZUMAB OZOGAMICIN vs INSULIN ASPART INOTUZUMAB OZOGAMICIN vs INSULIN ASPART\INSULIN DEGLUDEC INOTUZUMAB OZOGAMICIN vs INSULIN BEEF INOTUZUMAB OZOGAMICIN vs INSULIN DEGLUDEC

Related Pages

INOTUZUMAB OZOGAMICIN Full Profile All Hyperphosphataemia Reports All Drugs Causing Hyperphosphataemia INOTUZUMAB OZOGAMICIN Demographics